Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006
Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006
Takayuki Iwamoto 0 1 2 3 4 6 8 9 11
Naohito Fukui 0 1 2 3 4 6 8 9 11
Takayuki Kinoshita 0 1 2 3 4 6 8 9 11
Keisei Anan 0 1 2 3 4 6 8 9 11
Naoki Niikura 0 1 2 3 4 6 8 9 11
Masaaki Kawai 0 1 2 3 4 6 8 9 11
Naoki Hayashi 0 1 2 3 4 6 8 9 11
Kouichiro Tsugawa 0 1 2 3 4 6 8 9 11
Kenjiro Aogi 0 1 2 3 4 6 8 9 11
Takanori Ishida 0 1 2 3 4 6 8 9 11 13
Hideji Masuoka 0 1 2 3 4 6 8 9 10 11
Shinobu Masuda 0 1 2 3 4 6 8 9 11 12
Kotaro Iijima 0 1 2 3 4 5 6 8 9 11
Seigo Nakamura 0 1 2 3 4 6 7 8 9 11
Yutaka Tokuda 0 1 2 3 4 6 8 9 11
0 Department of Breast Surgery, National Cancer Center Hospital , Tokyo , Japan
1 The Japan Clinical Research Support Unit and the Public Health Research Foundation , Tokyo , Japan
2 Department of Breast and Endocrine Surgery, Okayama University Hospital , Okayama , Japan
3 Department of Breast Surgery, Shikoku Cancer Center , Matsuyama , Japan
4 Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine , Kawasaki , Japan
5 Department of Breast Oncology, Cancer Institute Hospital , Tokyo , Japan
6 Department of Breast Surgery, St. Luke's International Hospital , Tokyo , Japan
7 Division of Breast Surgical Oncology, Department of Surgery, Showa University , Tokyo , Japan
8 Department of Breast Surgery, Miyagi Cancer Center , Natori , Japan
9 Department of Breast and Endocrine Surgery, Tokai University School of Medicine , 143 Shimokasuya, Isehara, Kanagawa 259-1193 , Japan
10 Sapporo-kotoni Breast Clinic , Sapporo , Japan
11 Department of Surgery, Kitakyushu Municipal Medical Center , Kitakyushu , Japan
12 Department of Pathology, Nihon University School of Medicine , Tokyo , Japan
13 Department of Surgical Oncology, Graduate School of Medicine, Tohoku University , Sendai , Japan
188,265 cases have been registered. With the cooperation of the Non-Profit Organization Japan Clinical Research Support Unit (J-CRSU) and the Public Health Research Foundation, we have moved to the new system by the web registration from 2004. In 2006, the number of the registry for institutions was 352 and cases were 22,005. The number of institutions in this prognostic study was 134 and cases were 8788, with 39.9 %. An assessment of 5-year prognosis for cases registered in 2006 has been carried out, and here we report the results thanks to a number of efforts and cooperation. We believe that it is necessary to further promote the registry for contributions to improving breast cancer care and prognosis. Background characteristics of the patients are summarized in Table 1. The 5-year disease-free survival (DFS) was
Breast cancer; Prognosis; Report; Japan; Registry; 2006; The Japanese Breast Cancer Society
-
The prognostic study for the Japanese Breast Cancer
Society (JBCS) registry in 2006 was finally published here
(Figs. 1, 2, 3, 4, 5, 6, 7, 8, 9, Sup. Table 1–9). The JBCS
registry has been started from 1975. To 2003, for 29 years,
Electronic supplementary material The online version of this
article (doi:10.1007/s12282-015-0646-3) contains supplementary
material, which is available to authorized users.
& Yutaka Tokuda
Fig. 1 a, b Kaplan–Meier curves for relapse-free and overall survival
of all cases by tumor classification (cT-category). P values were
calculated using the log rank test. Tis non-invasive ductal carcinoma,
lobular carcinoma in situ, or Paget disease, T1a B0.5 cm, T1b
0.5 \ tumor B 1.0 cm, T1c 1.0 \ tumor B 2.0 cm, T2 2.0 \
tumor B 5.0 cm, T3 [5.0 cm, T4 tumor of any size with direct
extension to the chest wall and/or skin (ulceration or skin nodules) or
inflammatory carcinoma
Fig. 2 a, b Kaplan–Meier curves for relapse-free and overall survival
of all cases by regional lymph nodes status (cN-category) N0 no
regional lymph node metastases, N1 metastases in movable ipsilateral
level I, II axillary lymph node(s), N2 metastases in ipsilateral level I,
II axillary lymph nodes that are clinically fixed or matted OR
Metastases in clinically detected ipsilateral internal mammary nodes
in the absence of clinically evident axillary lymph node metastases,
N3 metastases in ipsilateral infraclavicular (level III axillary) lymph
node(s) with or without level I, II axillary lymph node involvement
OR Metastases in clinically detected ipsilateral internal mammary
lymph node(s) with clinically evident level I, II axillary lymph node
metastases OR Metastases in ipsilateral supraclavicular lymph
node(s) with or without axillary or internal mammary lymph node
involvement. P values were calculated using the log rank test
Fig. 4 a, b Kaplan–Meier curves for relapse-free and overall survival of cases without neoadjuvant therapy by pathological tumor size (pT size).
Tumor size is a marker of invasiveness. P values were calculated using the log rank test
Fig. 5 a, b Kaplan–Meier curves for relapse-free and overall survival of cases without neoadjuvant therapy by the number of metastatic (...truncated)